PeptiDream Inc. (PPTDF)
| Market Cap | 1.41B |
| Revenue (ttm) | 132.29M |
| Net Income (ttm) | -34.88M |
| Shares Out | n/a |
| EPS (ttm) | -0.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 48 |
| Average Volume | 18 |
| Open | 12.68 |
| Previous Close | 11.10 |
| Day's Range | 11.10 - 12.68 |
| 52-Week Range | 10.00 - 17.85 |
| Beta | 0.18 |
| RSI | 39.90 |
| Earnings Date | Nov 12, 2025 |
About PeptiDream
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates... [Read more]
Financial Performance
In 2024, PeptiDream's revenue was 46.68 billion, an increase of 62.57% compared to the previous year's 28.71 billion. Earnings were 15.01 billion, an increase of 394.70%.
Financial numbers in JPY Financial StatementsNews
PeptiDream: Opulent Dream Now A Reality
PeptiDream's PDPS platform offers a promising investment opportunity due to the new therapeutic class of macrocyclic peptide. Read my analysis of PPTDF stock.